Comparison of the Efficacy and Tolerability of Moclobemide and Fluvoxamine in Elderly Patients

Efficacy of treatment in older depressed patients: A systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants

“…Unfortunately, only 3 RCTs comparing different antidepressants and reporting remission data included only inpatients: in these studies no differences were found between TCAs and SSRIs or other antidepressants (Kok et al, 2007;Limosin et al, 2006;Waite et al, 1986). There were also no differences between classes of antidepressants in the five inpatient studies with response as outcome criterion (Bocksberger et al, 1993;Geretsegger et al, 1995;Kok et al, 2007;Limosin et al, 2006;Oslin et al, 2003) and in 5 studies with no extractable data to enter our meta-analysis (Altamura et al, 1989b;Bloeink et al, 1985;De Vanna et al, 1990;Eklund et al, 1985;Siegfried and O'Connolly, 1986).…”

“…In the 27 RCTs that used our secondary outcome criterion response, no significant difference could be demonstrated between TCAs and SSRIs (11 studies with OR 0.85; 95% CI = 0.69-1.04) (Bondareff et al, 2000;Cohn et al, 1990;Feighner and Cohn, 1985;Forlenza et al, 2001;Geretsegger et al, 1995;Hutchinson et al, 1991;Kyle et al, 1998;Limosin et al, 2006;Rahman et al, 1991;Wakelin, 1986;Wehmeier et al, 2005), nor between TCAs and other antidepressants (7 studies with OR 1.29; 95% CI = 0.95-1.75) (Hoyberg et al, 1996;Kok et al, 2007;Mahapatra and Hackett, 1997;Nair et al, 1995;Schifano et al, 1990;Tignol et al, 1998;Trick et al, 2004), nor between SSRIs and other antidepressants (9 studies with OR 1.81; 95% CI = 0.85-3.89) (Allard et al, 2004;Bocksberger et al, 1993;Dalery and Aubin, 2001;Dorman, 1992;Guelfi et al, 1999;Karlsson et al, 2000;Oslin et al, 2003;Schatzberg et al, 2002;Weihs et al, 2000). Excluding both studies (Karlsson et al, 2000;Oslin et al, 2003) that included a small minority of patients with dementia and depression did not have a significant change on the results.…”

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

“…A total of five exclusively inpatient RCTs contrasted MOC with other drugs (see Table 4): two with clomipramine (Danish University Antidepressant Group 1993; Guelfi et al 1992), and one each versus amitriptyline (Norman et al 1985), fluoxetine (Prozac) (Gattaz et al 1995), and fluvoxamine (Luvox) (Bocksberger et al 1993 Abbreviations: IMI ϭ imipramine; CMI ϭ clompiramine; ISO ϭ isocarboxazid; AMI ϭ amitriptyline; FLV ϭ fluvoxamine; AMIN ϭ aminetipine; MAP ϭ maprotiline; DOX ϭ doxepin; DOT ϭ dothiepin; PBO ϭ placebo. Figure 1.…”

“…Comparators included imipramine Abbreviations: FLV ϭ fluvoxamine, FLU ϭ fluoxetine. (Pancheri et al 1994), mianserin (De Vanna et al 1990;Tiller et al 1990), fluvoxamine (Bocksberger et al 1993), and nortriptyline (Aventyl) (Nair et al 1995b). The ITT response rate was 47.8% (8.0%), and the AT response rate was 69.9% (6.4%).…”

North of England evidence-based guideline development project: summary version of guidelines for the choice of antidepressants for depression in primary care

“…Analysis of the comparative efficacy of SSRIs and tricyclic antidepressants in in-patients (judged likely to be a more severely affected group) provided a slightly larger estimate of effect favouring tricyclic antidepressants, though again non-significant. The overall estimate of effect in this grouping of studies 8,16,27,35,44,47,67,69,73,74,77,80,81,82,86,88,91,94,98,99,105,108,111,118,120,127 (using a random effects model) was 0.10 (95% CI -0.072 to 0.272, Q = 49.1, d.f. = 22, P = 0.008).…”